Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.
microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation.
Researchers show that the protein CCN4 positively regulates the generation of cartilage matrix, which are depleted in osteoarthritis.
DNA, RNA, protein -- the end. Or is it? Until recently, the pattern used to encode genetic information into our cells was considered to be relatively straightforward: four letters (A,G,C,T) for DNA and four (A,G,C,U) for RNA. This equation, however, turned out to be oversimplified -- RNA was holding out.
RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.
Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).
RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
Viruses are able to redirect the functioning of cells in order to infect them. Inspired by their mode of action, scientists from the CNRS and Université de Strasbourg have designed a "chemical virus" that can cross the double lipid layer that surrounds cells, and then disintegrate in the intracellular medium in order to release active compounds.
EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.
Integrated DNA Technologies (IDT) will host an informative webinar, entitled ‘Knockdown of lncRNAs: exploring RNAi and antisense oligo methods’, on Tuesday, August 25, 2015. Kim Lennox, a research scientist at IDT and expert in the suppression of gene expression, will present the webinar at 9 am and 1 pm Central Standard Time.
Researchers at Oregon State University have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors.
Idiopathic pulmonary fibrosis is a very aggressive form of pulmonary fibrosis and has a particularly poor prognosis. This fatal disease, for which so far no causal therapies exist, is characterized by a massive deposition of connective and scar tissue in the lung, which leads to a progressive loss of lung function and ultimately death.
When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
Scientists from the University of Leeds have uncovered the most comprehensive list yet of genes implicated in a group of common inherited diseases.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA).
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).
In a new study published in the Protein & Cell, Chen-Yu Zhang's group at Nanjing University reports that small non-coding RNAs in maternal food can transfer through placenta to regulate fetal gene expression.
Researchers at Case Western Reserve University combined finely crafted nanoparticles with one of nature's potent disrupters to prevent the spread of triple-negative breast cancer in mouse models.
Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice.
An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, which was successfully tested in mice, were published online in the Journal of Investigative Dermatology.